The company proposes to make it available in both pre-filled syringe and pen options.
News
Savolitinib found to help treatment-resistant lung cancer in combo with AZ’s Tagrisso
The news was announced at the American Association for Cancer Research (AACR) annual meeting.
NHS to double diabetes prevention programme after patients lose 60,000kg collectively
The programme is set to include around 200,000 people annually.
Roche’s ipatasertib combo shows early promise in triple-negative breast cancer
The results showed a 73% overall response rate irrespective of PD-L1 status.
Venue announced for the International Clinical Researcher of the Year gala dinner & awards ceremony!
The 20th International Clinical Researcher of the Year competition gala dinner & awards ceremony will be taking place at The Chelsea Harbour Hotel in central London on 16th May.
IGEM gets further funding for cancer drugs
The £750,000 grant will go to developing novel IgE antibodies, targeting HER2.
Holobiome and J&J collaborate for second time for microbiome therapeutics
The partnership follows a similar agreement with the company that was announced in January of 2018.
New test could diagnose nine in 10 endometriosis cases
The current average time for an endometriosis diagnosis can be as long as seven years.
PharmaTimes announce brand new partnership for this year’s Communications Team of the Year Charity Challenge
As today marks World Autism Awareness Day, PharmaTimes are proud to announce that this year’s highly respected Charity Challenge will be partnering with ‘Autistica’ – the UK’s leading Autism research charity.
European approval for Teva’s migraine drug Ajovy
The drug is a pre-filled syringe for the prophylaxis of migraine in adults who have at least four migraine days per month.
NICE nod for breast cancer delay drug
Eli Lilly’s Verzenio has been recommended for use within the Cancer Drugs Fund by NICE.
AZ’s Selumetinib granted US Breakthrough Therapy Designation
The BTD is for the treatment of paediatric patients aged three years and older with neurofibromatosis type 1 (NF1).
Circassia’s COPD drug gets FDA approval
The approval is based on data from three Phase III studies, ACLIFORM, AUGMENT and AMPLIFY.
NHS prescribed nearly 70M antidepressants last year as rates double in a decade
The number dispensed last year was almost double the 36 million recorded a decade ago in 2008.
FDA green light for Merck’s Mavenclad
The drug is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment.
